Wednesday, October 21, 2020 8:08:18 PM
Going by the historical performance, we believe that the stock price of Mylan (NYSE: MYL), a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current levels. MYL stock trades at $15 currently and it is down 35% from the pre-Covid high of $23 seen in February. Also, MYL stock has declined 2% from the low of $16 seen in March 2020, significantly underperforming the broader markets, with the S&P500 seeing a 53% rise over the same period, as the Fed stimulus largely put investor concerns about the near-term survival of companies to rest.
Mylan Stock Has Over 45% Upside
For Mylan, the sales have trended better than many of the other pharmaceutical companies in this pandemic, as we discuss in the sections below. Mylan’s integration with Pfizer’s Upjohn division will help the company expand geographically, as Upjohn has a strong leadership position in China and emerging markets while Mylan has a significant presence in the U.S. and Europe. In view of the economic growth and with a vaccine in sight for the coronavirus, we believe that MYL stock has more than 45% upside in the near future. Our conclusion is based on our detailed analysis of Mylan stock performance during the current crisis with that during the 2008 recession in an interactive dashboard analysis.
2020 Coronavirus Crisis
Timeline of 2020 Crisis So Far:
12/12/2019: Coronavirus cases first reported in China
1/31/2020: WHO declares a global health emergency.
2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, as Covid-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid a Saudi-led price war
From 3/24/2020: S&P 500 recovers 56% from the lows seen on Mar 23, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.
Mylan Inc. (MYL)
https://www.forbes.com/sites/greatspeculations/2020/10/21/mylan-stock-has-over-45-upside/#379d5c2b1464
Mylan Stock Has Over 45% Upside
For Mylan, the sales have trended better than many of the other pharmaceutical companies in this pandemic, as we discuss in the sections below. Mylan’s integration with Pfizer’s Upjohn division will help the company expand geographically, as Upjohn has a strong leadership position in China and emerging markets while Mylan has a significant presence in the U.S. and Europe. In view of the economic growth and with a vaccine in sight for the coronavirus, we believe that MYL stock has more than 45% upside in the near future. Our conclusion is based on our detailed analysis of Mylan stock performance during the current crisis with that during the 2008 recession in an interactive dashboard analysis.
2020 Coronavirus Crisis
Timeline of 2020 Crisis So Far:
12/12/2019: Coronavirus cases first reported in China
1/31/2020: WHO declares a global health emergency.
2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, as Covid-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid a Saudi-led price war
From 3/24/2020: S&P 500 recovers 56% from the lows seen on Mar 23, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.
Mylan Inc. (MYL)
https://www.forbes.com/sites/greatspeculations/2020/10/21/mylan-stock-has-over-45-upside/#379d5c2b1464
Recent VTRS News
- Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting • PR Newswire (US) • 04/10/2026 10:59:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 08:32:48 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:31:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:30:52 PM
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) • PR Newswire (US) • 03/23/2026 10:59:00 AM
- Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 • PR Newswire (US) • 03/19/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:04:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:03:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:16 AM
- Viatris tops forecasts as earnings and revenue beat expectations • IH Market News • 02/26/2026 02:45:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:52:59 PM
- Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 02/26/2026 11:59:00 AM
- Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend • PR Newswire (US) • 02/26/2026 11:55:00 AM
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia • PR Newswire (US) • 02/25/2026 11:59:00 AM
- Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 • PR Newswire (US) • 02/03/2026 09:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:30:31 PM
- Viatris Appoints Matthew J. Maletta as Chief Legal Officer • PR Newswire (US) • 02/03/2026 01:30:00 PM
- Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure • PR Newswire (US) • 01/20/2026 11:59:00 AM
- Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer • PR Newswire (US) • 01/08/2026 02:05:00 PM
- Viatris Provides Pipeline Update on Four Regulatory Milestones • PR Newswire (US) • 12/18/2025 11:59:00 AM
- Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 12/17/2025 11:59:00 AM
- Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back • PR Newswire (Canada) • 12/15/2025 02:00:00 PM
